# Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00053391** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Erlangen** · enrollment: 62 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** recombinant CD40-ligand
- **BIOLOGICAL:** therapeutic autologous dendritic cells

## Key facts

- **NCT ID:** NCT00053391
- **Lead sponsor:** University Hospital Erlangen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-06
- **Final completion:** 2007-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053391, "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00053391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*